209 related articles for article (PubMed ID: 31838008)
1. Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours.
Lassen U
Lancet Oncol; 2020 Feb; 21(2):193-194. PubMed ID: 31838008
[No Abstract] [Full Text] [Related]
2. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
Frampton JE
Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
[TBL] [Abstract][Full Text] [Related]
3. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
4. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G
ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659
[TBL] [Abstract][Full Text] [Related]
6. Entrectinib: First Global Approval.
Al-Salama ZT; Keam SJ
Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
[TBL] [Abstract][Full Text] [Related]
7. Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Dziadziuszko R; Hung T; Wang K; Choeurng V; Drilon A; Doebele RC; Barlesi F; Wu C; Dennis L; Skoletsky J; Woodhouse R; Li M; Chang CW; Simmons B; Riehl T; Wilson TR
Mol Oncol; 2022 May; 16(10):2000-2014. PubMed ID: 35338679
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
Mercier F; Djebli N; González-Sales M; Jaminion F; Meneses-Lorente G
Cancer Chemother Pharmacol; 2022 Mar; 89(3):363-372. PubMed ID: 35118559
[TBL] [Abstract][Full Text] [Related]
9. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
[TBL] [Abstract][Full Text] [Related]
10. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
Araujo JM; Gomez AC; Pinto JA; Rolfo C; Raez LE
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):192-198. PubMed ID: 33290717
[TBL] [Abstract][Full Text] [Related]
11. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
[TBL] [Abstract][Full Text] [Related]
12. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
Osman HM; Tuncbilek M
Curr Med Chem; 2022; 29(15):2602-2616. PubMed ID: 34521321
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Fan Y; Drilon A; Chiu CH; Loong HHF; Siena S; Krzakowski M; Dziadziuszko R; Zeuner H; Xue C; Krebs MG
Clin Lung Cancer; 2024 Mar; 25(2):e81-e86.e4. PubMed ID: 38245456
[No Abstract] [Full Text] [Related]
14. Matching-adjusted indirect comparison: entrectinib versus crizotinib in
Chu P; Antoniou M; Bhutani MK; Aziez A; Daigl M
J Comp Eff Res; 2020 Aug; 9(12):861-876. PubMed ID: 32648475
[No Abstract] [Full Text] [Related]
15. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
Demetri GD; De Braud F; Drilon A; Siena S; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Lin JJ; Goto K; Lee J; Bazhenova L; John T; Fakih M; Chawla SP; Dziadziuszko R; Seto T; Heinzmann S; Pitcher B; Chen D; Wilson TR; Rolfo C
Clin Cancer Res; 2022 Apr; 28(7):1302-1312. PubMed ID: 35144967
[TBL] [Abstract][Full Text] [Related]
16. Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic
Ardini E; Siena S
ESMO Open; 2020 Sep; 5(5):e000867. PubMed ID: 32907817
[No Abstract] [Full Text] [Related]
17. Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC.
Coleman N; Yousaf N; Arkenau HT; Welsh L; Popat S
J Thorac Oncol; 2020 Aug; 15(8):e142-e144. PubMed ID: 32718541
[No Abstract] [Full Text] [Related]
18. Evaluating entrectinib as a treatment option for non-small cell lung cancer.
Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Opin Pharmacother; 2020 Nov; 21(16):1935-1942. PubMed ID: 32736487
[TBL] [Abstract][Full Text] [Related]
19. Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.
Seo SW; Han DG; Choi E; Park T; Byun JH; Cho HJ; Jung IH; Yoon IS
Biomed Pharmacother; 2022 Feb; 146():112520. PubMed ID: 34902744
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in
Doebele RC; Perez L; Trinh H; Martinec M; Martina R; Riehl T; Krebs MG; Meropol NJ; Wong WB; Crane G
J Comp Eff Res; 2021 Dec; 10(17):1271-1282. PubMed ID: 34427452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
